Vaxart to Participate in BTIG Infectious Disease Day 2026
Rhea-AI Summary
Vaxart (OTCQX: VXRT), a clinical-stage biotech developing oral recombinant vaccines, announced participation in BTIG Infectious Disease Day 2026 on June 16, 2026.
The virtual event will feature 1x1 meetings between Vaxart management and institutional investors arranged through BTIG representatives.
Positive
- None.
Negative
- None.
News Market Reaction – VXRT
In the Jun 9 session, VXRT declined 3.12%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | Proxy solicitation | Neutral | -5.4% | Company urged votes for its six director nominees ahead of July 16 meeting. |
| Jun 01 | Definitive proxy filed | Neutral | -2.3% | Filed definitive proxy and highlighted pipeline, funding, and leadership alignment. |
| May 19 | Preliminary proxy filed | Neutral | -1.6% | Preliminary proxy and letter seeking support for current Board amid trial progress. |
| May 07 | Q1 2026 earnings | Positive | -5.4% | Reported Q1 revenue, net income, BARDA funding and extended cash runway. |
| May 01 | Investor event notice | Neutral | +0.0% | Announced May 8 virtual stockholder fireside chat and Q1 2026 earnings timing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including proxy and earnings updates, often coincided with negative price reactions, even when fundamentals like revenue and cash runway were highlighted as strengths.
Over the last few months, Vaxart has focused on governance, proxy matters, and advancing its BARDA-supported oral vaccine programs. Earnings on May 7, 2026 showed revenue of $39.2 million and net income of $5.2 million, with cash runway into Q2 2027, yet the stock fell -5.41%. Subsequent proxy-related communications on May 19, June 1, and June 8 also saw predominantly negative price reactions, indicating a pattern of weak market response to recent updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in the BTIG Infectious Disease Day 2026 on June 16.
BTIG Infectious Disease Day 2026
Date: Tuesday, June 16, 2026
Format: 1x1 Meetings
Location: Virtual
Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations:
FINN Partners
IR@vaxart.com
